Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Neurosurgery. 2010 Jul;67(1):27-32; discussion 32-3. doi: 10.1227/01.NEU.0000370978.31405.A9.
To analyze the factors associated with anterior pituitary deficits after pituitary adenoma stereotactic radiosurgery (SRS).
The tumor, pituitary stalk, and pituitary gland were segmented on the dose plans of 82 patients (secreting tumors, n = 53; nonsecreting tumors, n=29) for dose-volume analysis. No patient had undergone prior radiation therapy and all patients had at least 12 months of endocrinological follow-up (median, 63 months; mean, 69 months; range, 13-134).
Thirty-four patients (41%) developed new anterior pituitary deficits at a median of 32 months (range, 2-118) after SRS. The risk of developing new anterior pituitary deficits was 16% and 45% at 2 and 5 years, respectively. Multivariate analysis of the entire group showed that poor visualization of the pituitary gland (hazard ratio [HR]=2.63, 95% confidence interval [CI]=1.10-6.25, P=.03) was associated with a higher rate of new anterior pituitary deficits. Dosimetric analysis of 60 patients whose pituitary gland could be clearly identified showed that increasing mean pituitary gland radiation dose correlated with new anterior pituitary deficits (HR=1.11, 95% CI=1.02-1.20, P=.02). New anterior pituitary deficits stratified by mean pituitary gland radiation dose: <or=7.5 Gy, 0% (0/7); 7.6 to 13.2 Gy, 29% (7/24); 13.3 to 19.1 Gy, 39% (9/23); >19.1 Gy, 83% (5/6).
New endocrine deficits after pituitary adenoma radiosurgery were correlated with increasing radiation dose to the pituitary gland. Methods that limit the radiation dose to the pituitary gland during SRS may increase the probability of preserving pituitary function.
分析经蝶窦立体定向放射外科(SRS)治疗垂体腺瘤后发生垂体前叶功能减退的相关因素。
对 82 例患者(分泌性肿瘤 53 例,无分泌性肿瘤 29 例)的剂量计划进行肿瘤、垂体柄和垂体的分割,以进行剂量体积分析。所有患者均未接受过放射治疗,且均有至少 12 个月的内分泌随访(中位数 63 个月;平均 69 个月;范围 13-134 个月)。
34 例(41%)患者在 SRS 后中位数为 32 个月(范围 2-118 个月)时出现新的垂体前叶功能减退。2 年和 5 年时新发垂体前叶功能减退的风险分别为 16%和 45%。对所有患者进行的多变量分析显示,垂体显示不佳(风险比 [HR]=2.63,95%置信区间 [CI]=1.10-6.25,P=.03)与新发垂体前叶功能减退的发生率较高相关。对 60 例可明确识别垂体的患者进行的剂量学分析显示,平均垂体照射剂量的增加与新发垂体前叶功能减退相关(HR=1.11,95% CI=1.02-1.20,P=.02)。按平均垂体照射剂量分层的新发垂体前叶功能减退发生率:<or=7.5 Gy,0%(0/7);7.6-13.2 Gy,29%(7/24);13.3-19.1 Gy,39%(9/23);>19.1 Gy,83%(5/6)。
垂体腺瘤放射外科治疗后出现新的内分泌功能减退与垂体照射剂量的增加相关。在 SRS 期间限制垂体照射剂量的方法可能会增加保留垂体功能的概率。